INM Financials

Income Statement
MetricQ4 2026Q3 2026Q2 2026Q1 2026Q4 2025
Revenue
0
0
-100.0%
820.2K
-26.8%
1.1M
0
Cost of Revenue
0
0
-100.0%
636.0K
-11.3%
717.0K
0
Gross Profit
0
0
-100.0%
184.2K
-54.3%
403.2K
0
Operating Expenses
3.2M
+14.0%
2.8M
+22.2%
2.3M
+6.4%
2.2M
+14.7%
1.9M
R&D
805.7K
-21.2%
1.0M
+62.2%
630.6K
+8.4%
581.6K
+0.8%
577.3K
SG&A
2.4M
+35.3%
1.7M
+7.5%
1.6M
+5.8%
1.5M
+21.7%
1.3M
Operating Income
-3211149
-14.0%
-2816353
-32.8%
-2120738
-20.2%
-1763670
+6.6%
-1888440
EBITDA
-3162790
-14.4%
-2765844
-33.8%
-2067537
-20.9%
-1710468
+6.8%
-1835688
Net Income
-5839392
-96.9%
-2966336
-46.3%
-2028223
-17.4%
-1726899
+3.4%
-1788311
EPS (Basic)
$-1.34
-83.6%
$-0.73
-43.1%
$-0.51
-15.9%
$-0.44
+63.6%
$-1.21
EPS (Diluted)
$-1.34
-83.6%
$-0.73
-43.1%
$-0.51
-15.9%
$-0.44
+63.6%
$-1.21
Shares (Diluted)
4.7M
+16.0%
4.0M
+2.4%
4.0M
+0.0%
4.0M
+167.0%
1.5M
InMed Pharmaceuticals Inc. Common Shares (INM) โ€” Financials